Cargando…
Phase IIa Clinical Biomarker Trial of Dietary Arginine Restriction and Aspirin in Colorectal Cancer Patients
SIMPLE SUMMARY: The authors present a phase IIa clinical biomarker trial of colorectal cancer (CRC) survivors treated with a polyamine-inhibitory regimen (dietary arginine restriction plus daily aspirin 325 mg) as a potential future strategy for tertiary prevention of CRC (i.e., preventing colorecta...
Autores principales: | Zell, Jason A., Taylor, Thomas H., Albers, C. Gregory, Carmichael, Joseph C., McLaren, Christine E., Wenzel, Lari, Stamos, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093153/ https://www.ncbi.nlm.nih.gov/pubmed/37046763 http://dx.doi.org/10.3390/cancers15072103 |
Ejemplares similares
-
Risk of second primary colorectal cancer among colorectal cancer cases: A population-based analysis
por: Raj, Kavitha P., et al.
Publicado: (2011) -
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas
por: Raj, K P, et al.
Publicado: (2013) -
Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas
por: Zell, Jason A., et al.
Publicado: (2012) -
Aspirin and colorectal cancer.
por: La Vecchia, C., et al.
Publicado: (1997) -
Aspirin Recapitulates Features of Caloric Restriction
por: Pietrocola, Federico, et al.
Publicado: (2018)